Functional Characterization of RELA Fusion Ependymoma as a Basis for Therapeutic Targeting |
St. Jude Children’s Research Hospital / Stephen Mack, PhD |
'A' Award Grants |
2018 |
Tennessee |
WWOX as a Signal Mediator in Pediatric Osteosarcoma |
The Ohio State University / Rami Aqeilan |
'A' Award Grants |
2009 |
Ohio |
Exploiting glypican diversity in neuroblastoma plasticity with bicistronic CAR T cell targeting |
Children’s Hospital of Philadelphia / Kristopher Bosse, MD |
'A' Award Grants |
2022 |
Pennsylvania |
Exploiting the Differentiation Potential of Pediatric High-Grade Glioma to Discover Novel Therapeutic Opportunities |
Dana-Farber Cancer Institute / Mariella Filbin, MD/PhD |
'A' Award Grants |
2019 |
Massachusetts |
Circulating Tumor Biomarkers: New Paradigms for Management of Neuroblastoma |
University of Chicago / Mark Applebaum, PhD |
'A' Award Grants |
2021 |
Illinois |
Genetically Modified, Cord Blood Derived Natural Killer Cell Therapy for High Grade Pediatric Brain Tumors |
Children’s Research Institute / Conrad Russell Cruz, MD, PhD |
'A' Award Grants |
2015 |
District of Columbia |
Investigating the Role of Genetic and Epigenetic Variation in Risk of Childhood Acute Lymphoblastic Leukemia in Down Syndrome |
University of California San Francisco / Adam de Smith, Ph.D. |
'A' Award Grants |
2014 |
California |
Novel Approaches to AML Differentiation Therapy |
Dana-Farber Cancer Institute / Andrew Lane, MD/PhD |
'A' Award Grants |
2017 |
Massachusetts |
Prognostic and Therapeutic Significance of Stem Cell Heterogeneity in AML |
Fred Hutchinson Cancer Research Center / Roland Walter, MD, PhD |
'A' Award Grants |
2012 |
Washington |
The Role of Inherited MLL3 Single Nucleotide Variants and Fetal Epigenetic Programming in Infant Leukemogenesis |
Washington University / Jeffrey Magee, MD/PhD |
'A' Award Grants |
2016 |
Missouri |